GlassScriptPhysician profile
Richard Moro
NPI 1700859006
$24,728.31
in general payments reported to CMS, 2019-2025
58 companies · $4,109 in 2025
The $4,109 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,062 · 2022: $5,325 · 2023: $4,736 · 2024: $5,497 · 2025: $4,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,151.78 |
| Education | $190.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,891.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,138.56 | 2021-2025 | Farxiga, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,810.49 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,344.51 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $1,272.91 | 2021-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,215.02 | 2021-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $1,071.78 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $899.89 | 2022-2025 | |
| Alkermes, INC. | $883.20 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Pfizer INC. | $792.59 | 2021-2025 | |
| Lilly USA, LLC | $743.63 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $623.13 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Amgen INC. | $567.64 | 2021-2025 | Otezla, Repatha, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $503.74 | 2021-2025 | Trintellix, Glassia |
| Corium, LLC | $451.22 | 2022-2024 | Azstarys |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Moro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.